TeijinTEIJIN LIMITED3401東証プライム繊維製品FY ending Mar 2026, consolidated, IFRS

Teijin FY ending Mar 2026 results

About 40% of Teijin's sales come from Fiber and Products Converting, with Materials and Helthcare making up much of the rest.

It lost about ¥8 for every ¥100 of sales at the operating level.

Revenue changed -13.2% from the prior year.

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue for the FY ending Mar 2026 was ¥873.2B, down 13.2% from ¥1.01T the year before.
Operating income stayed negative at -¥70.7B, after -¥71.8B in the prior year.
Net income swung from a ¥28.3B profit to a loss of -¥88B.
Cash generation improved, though: operating cash flow rose 41.3% to ¥98.7B, and free cash flow grew to ¥38.7B.

Impairment losses in the aramid and healthcare businesses were the main reason for the operating and net losses
Materials sales and profit fell as a large scheduled maintenance shutdown hit aramid, carbon fiber volumes dropped, and tougher competition pushed prices down
Healthcare profit rose thanks to more rentals of home medical devices, such as sleep apnea (CPAP) machines and home oxygen units, plus license income
Teijin sold its North American composites business and Teijin Nakashima Medical, so both left the group's accounts

In aramid and carbon fiber, competitors adding capacity has loosened supply and keeps pressure on prices; recovery depends on the ongoing cost overhaul
Drug sales are being squeezed by government price cuts and the spread of generics
Supply chain disruption, for example from instability in the Middle East, could delay raw materials or raise costs

Annual securities report (FY ending Mar 2026) / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual securities report (FY ending Mar 2026) / 事業等のリスク

FY ending Mar 2025 → FY ending Mar 2026

For every ¥100 Teijin sells, how much goes where, and how much is kept.

FY ending Mar 2026

Gross margin18.5%

Operating margin-8.1%

Net margin-10.1%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Fiber and Products Converting¥350.1B
40%
Op. margin 4.9%Industry: Specialty Trading & Wholesale
Materials¥338.6B
39%
Op. margin 0.0%Industry: Chemicals
Helthcare¥138.6B
16%
Op. margin 9.7%Industry: Pharmaceuticals
Other¥46B
5%
Op. margin 9.9%Industry: Batteries

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第160期(2025/04/01－2026/03/31)
ID S100YCMK2026-06-18Open
EDINET (FSA Japan)
有価証券報告書－第159期(2024/04/01－2025/03/31)
ID S100W4FO2025-06-25Open
EDINET (FSA Japan)
有価証券報告書－第158期(2023/04/01－2024/03/31)
ID S100TO4E2024-06-20Open
EDINET (FSA Japan)
有価証券報告書－第157期(2022/04/01－2023/03/31)
ID S100QZX02023-06-21Open
EDINET (FSA Japan)
有価証券報告書－第156期(令和3年4月1日－令和4年3月31日)
ID S100O9JF2022-06-22Open
EDINET (FSA Japan)
訂正有価証券報告書－第155期(令和2年4月1日－令和3年3月31日)
ID S100M4OK2021-08-10Open

Extracted from XBRL: 44 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.